Sign in
Taking people in South AfricaPhase 4

Continued drug access for children with HIV who finished Gilead studies

Gives continued study medicine to children and teens with HIV who completed earlier studies.

Key facts

Who runs it
Gilead Sciences
Where
Cape Town, Durban, Johannesburg, Paarl, Pretoria, and Soweto, South AfricaSee the 7 sitesAlso in 5 other countries, 10 sites
Registry title
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
Status
Recruiting
Phase
Phase 4
People taking part
350 people, planned
Started
27 Aug 2024
Expected to end
Mar 2034
Type of study
Interventional, 4 groups
Treatments tested
  • F/TAF (High Dose Tablet)
  • F/TAF (Low Dose Tablet)
  • F/TAF (Lowest Dose Tablet)
  • F/TAF (High Dose TOS)
  • F/TAF (Low Dose TOS)
  • F/TAF (Lowest Dose TOS)
  • E/C/F/TAF
  • E/C/F/TAF (Low Dose)
  • Cobicistat (High Dose)
  • Cobicistat (Low Dose)
  • Cobicistat (TOS)
  • B/F/TAF (High Dose)
  • B/F/TAF (Low Dose)
  • B/F/TAF (High Dose TOS)
  • B/F/TAF (Low Dose TOS)
  • B/F/TAF (Lowest Dose TOS)
  • 3rd ARV Agent
  • Nucleos(t)ide reverse transcriptase inhibitors (NRTI)
  • ATV
  • DRV
  • Lopinavir Boosted with ritonavir (LPV/r)
Record updated
6 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and adolescents with HIV-1 who finished one of the listed Gilead parent studies. It gives continued access to the study drug and checks safety.

Age
From 1 Month of age.
Sex
All sexes can join.
Disease stage
HIV-1 infection; no particular stage is named.
Earlier treatment
Must have completed one of these parent studies: GS-US-292-0106, GS-US-380-1474, GS-US-311-1269, or GS-US-216-0128.
Biomarker or test result
For switching to B/F/TAF on Day 1, plasma HIV RNA must be below 50 copies/mL at the last parent study visit.

Main reasons for not taking part

  • Plans to switch to B/F/TAF on Day 1 with plasma HIV RNA ≥ 50 copies/mL at the last parent study visit
  • Plans to switch to B/F/TAF with an ongoing Grade 3 or 4 drug-related adverse event or lab abnormality
  • Earlier stop of any B/F/TAF component because of toxicity or intolerance
  • Known allergy to a component of the study drug when planning to switch to B/F/TAF
  • Ongoing treatment with or earlier use of prohibited medications

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Completed an applicable parent study: GS-US-292-0106, GS-US-380-1474, GS-US-311-1269, or GS-US-216-0128, and gave consent to study participation

Who cannot take part

  • Individuals planning to switch to B/F/TAF on Day 1 with plasma HIV RNA ≥ 50 copies/mL during the last parent study visit prior to screening/Day 1 visit; Note: individuals planning to switch after Day 1 must not have plasma HIV RNA ≥ 50 copies/mL (or detectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL)
  • For those on B/F/TAF or planning to switch to B/F/TAF: previous treatment discontinuation of any component of B/F/TAF due to toxicity or intolerance
  • Ongoing treatment with or prior use of any prohibited medications; Note: Other protocol defined Inclusion/Exclusion criteria may apply
  • For those planning to switch to B/F/TAF: known hypersensitivity to any component of the study drug, its metabolites, or formulation excipients
  • Individuals planning to switch to B/F/TAF with any ongoing Grade 3 or 4 drug-related AE or clinically relevant Grade 3 or 4 drug-related laboratory abnormality (confirmed on repeat) related to any component of B/F/TAF prior to treatment switch

Where in South Africa

Also in 5 other countries, 10 sites

  • University of StellenboschCape Town, South AfricaTaking people
  • Enhancing Care FoundationDurban, South AfricaTaking people
  • Rahima Moosa Mother and Child HospitalJohannesburg, South AfricaTaking people
  • WITS RHI Research CentreJohannesburg, South AfricaTaking people
  • Be Part Yoluntu CentrePaarl, South AfricaTaking people
  • The Aurun InstitutePretoria, South AfricaTaking people
  • Perinatal HIV Research UnitSoweto, South AfricaTaking people

About the trial

What the trial wants to find out

The goal of this clinical study is to provide continued access to the study drug(s) to children and adolescents with human immunodeficiency virus type 1 (HIV-1) who completed their participation in an applicable parent study and to monitor for adverse events.

Read full original descriptionShow less

The primary objectives of this study are as follows:

* To provide continued access to the study drug received in the parent protocol or switch to bictegravir/emtricitabine/tenofovir (B/F/TAF) for participants who completed a Gilead parent study evaluating drugs for HIV treatment. * To evaluate the safety of the study drug(s) in participants with HIV-1.

The 4 groups in the trial

  • Rollover from Parent Study: GS-US-311-1269: Parent Study Drug (F/TAF) or B/F/TAFTreatment being tested

    Participants will continue to take the study drug they were taking in the parent study, emtricitabine/tenofovir alafenamide (F/TAF) along with a 3rd antiretroviral (ARV) agent. The dose of F/TAF will be based on the weight of the participant, ranging between 120/15 mg to 200/25 mg. The dose of F/TAF will be different when given with the boosted and the unboosted 3rd ARV agent: F/TAF (High Dose Tablet) for unboosted 3rd ARV agent; F/TAF (Low Dose Tablet) for the boosted 3rd ARV agent. Participants may switch to B/F/TAF, at a dose based on participant's weight.

    Treatment: F/TAF (High Dose Tablet), F/TAF (Low Dose Tablet), F/TAF (Lowest Dose Tablet), B/F/TAF (High Dose), B/F/TAF (Low Dose), B/F/TAF (High Dose TOS), and 3rd ARV Agent

  • Rollover from Parent Study: GS-US-292-0106: Parent Study Drug (E/C/F/TAF) or B/F/TAFTreatment being tested

    Participants will continue to take the study drug they were taking in the parent study, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF). The dose of E/C/F/TAF will be based on the weight of the participant, ranging between 90/90/120/6 mg to 150/150/200/10 mg. Participants may switch to B/F/TAF at a dose based on participant's weight.

    Treatment: E/C/F/TAF, E/C/F/TAF (Low Dose), B/F/TAF (High Dose), and B/F/TAF (Low Dose)

  • Rollover Parent Study GS-US-216-0128: Parent Study Drug (Combination Drugs) or B/F/TAFTreatment being tested

    Participants will continue to take the following study drugs they were taking in the parent study: * Cobicistat (COBI) + DRV + NRTI backbone * COBI + ATV + NRTI backbone * F/TAF + DRV+ COBI * F/TAF + ATV+ COBI * F/TAF + LPV/r * F/TAF + 3rd unboosted agent The dose of F/TAF will be based on the weight of the participant, ranging between 15/1.88 mg and 200/25 mg, once daily. Additionally, the dose of COBI will be based on the weight of the participant, ranging between 30 mg and 150 mg, once or twice daily. Participants may switch to B/F/TAF at a dose based on participant's weight.

    Treatment: F/TAF (High Dose Tablet), F/TAF (Lowest Dose Tablet), F/TAF (High Dose TOS), F/TAF (Low Dose TOS), F/TAF (Lowest Dose TOS), Cobicistat (High Dose), Cobicistat (Low Dose), Cobicistat (TOS), B/F/TAF (High Dose), B/F/TAF (Low Dose), B/F/TAF (High Dose TOS), B/F/TAF (Low Dose TOS), B/F/TAF (Lowest Dose TOS), 3rd ARV Agent, Nucleos(t)ide reverse transcriptase inhibitors (NRTI), ATV, DRV, and Lopinavir Boosted with ritonavir (LPV/r)

  • Rollover from Parent Studies: GS-US-380-1474 and CO-US-380-5578: Parent Study Drug (B/F/TAF)Treatment being tested

    Participants will continue to take the study drug they were taking in the parent study, B/F/TAF. Participants who are diagnosed with HIV-1 infection in parent study CO-US-380-5578 and complete the study drug will continue to take the study drug they were taking in the parent study, B/F/TAF. The dose of B/F/TAF will be based on the weight of the participant.

    Treatment: B/F/TAF (High Dose), B/F/TAF (Low Dose), B/F/TAF (High Dose TOS), B/F/TAF (Low Dose TOS), and B/F/TAF (Lowest Dose TOS)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-label, Single-arm Study to Provide Continued Access to Study Drug to Participants Who Have Completed Pediatric Clinical Studies Involving Gilead HIV Treatments
Plain-language title
Continued drug access for children with HIV who finished Gilead studiesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 November 2026